Clinical Protocols & Pricing Verified: October 9, 2026

GLP-1 BMI Calculator: Do You Qualify for Treatment?

Use this free GLP-1 BMI calculator to see if you meet clinical eligibility guidelines for 503A compounded semaglutide ($49/mo) or tirzepatide ($99/mo) with no membership fees. Answer 3 quick questions to find out if you're eligible for compounded semaglutide or tirzepatide. Most adults with a BMI of 27+ qualify.

Takes 30 Seconds No Cost Instant Results
BMI Calculator

Calculate your BMI in seconds

Enter your height and weight below. We'll calculate your BMI and show your eligibility for GLP-1 medication.

Pounds (lbs)

Who qualifies for GLP-1 medication?

Most adults who meet one of the following criteria are eligible for compounded semaglutide or tirzepatide.

BMI ≥ 30

Classified as obese. You likely qualify for GLP-1 therapy without any additional conditions needed.

BMI 27–29.9 + Comorbidity

Overweight with high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea.

Age 18+

Must be 18 years or older to receive a prescription for GLP-1 weight loss medication.

No Contraindications

No personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome.

Simple Process

How to get started in 3 easy steps

From assessment to delivery in as few as 4 days. No office visits required.

Step 1

Complete online assessment

Answer a 5-minute health questionnaire covering your medical history, current medications, and weight loss goals.

Step 2

Provider review within 24 hours

A board-certified U.S. physician evaluates your profile and prescribes medication if clinically appropriate.

Step 3

Medication shipped to your door

Your prescription is compounded by a licensed 503A pharmacy and cold-shipped express in 3–5 business days.

Common qualifying conditions

If you have a BMI of 27+ and any of the following weight-related conditions, you may be eligible for GLP-1 medication.

Type 2 diabetes or prediabetes
High blood pressure (hypertension)
High cholesterol (dyslipidemia)
Obstructive sleep apnea
Cardiovascular disease
Polycystic ovary syndrome (PCOS)
Non-alcoholic fatty liver disease
Osteoarthritis related to excess weight

Frequently asked questions about eligibility

A BMI of 30 or higher generally qualifies you for GLP-1 medications like compounded semaglutide. If your BMI is between 27 and 29.9 and you have a weight-related health condition (such as type 2 diabetes, high blood pressure, or high cholesterol), you may also qualify. Use our free BMI calculator above to check your number instantly.

Yes. Adults with a BMI of 27–29.9 may qualify if they have at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. A board-certified provider will evaluate your full health profile during your online assessment.

You don't need to bring a formal diagnosis. During your online medical assessment, a board-certified provider will evaluate your health profile, medical history, and current conditions to determine eligibility. Simply answer the health questionnaire honestly and completely.

A licensed U.S. physician reviews your assessment within 24 hours. If clinically appropriate, they'll prescribe your medication. It's then compounded by a licensed 503A pharmacy and shipped to your door via express cold-chain delivery in 3–5 business days.

Yes. You must be 18 years or older to qualify for GLP-1 weight loss medication through our platform. All patients are evaluated by board-certified U.S. physicians who ensure the treatment is appropriate for your age and health profile.

If a provider determines that GLP-1 medication isn't right for you, you won't be charged. Your provider may suggest alternative weight management options based on your complete health profile. There's no obligation or risk in completing the assessment.

Active healthy lifestyle

Ready to find out
if you qualify?

Complete your online medical intake in minutes. A board-certified provider will review your profile and, if eligible, prescribe your medication — custom-compounded and cold-shipped express to your door. Introductory promo starting at $49/mo.

Start My Assessment →

2026 Verified GLP-1 Cash-Cost & U-100 Syringe Unit Benchmark

Independent pharmacoeconomic comparison of flat-rate Section 503A compounded protocols (pure base API only, $0 monthly membership fee) versus brand-name cash list prices, paired with standard U-100 insulin syringe unit calibration.

Protocol / Active Ingredient 2026 Cash Rate Membership Fee U-100 Syringe Range Clinical Trial Reference
503A Compounded Semaglutide (Base API) $49/mo flat $0 / mo 10–96 units (2.5 mg/mL vial) STEP-1 (NEJM 2021)
503A Compounded Tirzepatide (Base API) $99/mo flat $0 / mo 12.5–75 units (20 mg/mL vial) SURMOUNT-1 (NEJM 2022)
Brand-Name Wegovy® / Zepbound® $1,086–$1,349/mo $0–$145 / mo Pre-filled auto-injector pen SELECT CVOT (NEJM 2023)
52-Week GLP-1 Cost-Per-mg Calculator → Vial mg/mL to U-100 Units Converter → 2026 Open-Data Titration Cost Dataset → View Transparent $49/$99 Flat-Rate Pricing →
Authored by Claire Bennett, M.S. · Medically Reviewed by Dr. Elena Rivera, M.D.
Last Reviewed:
FDA Boxed Warning — Risk of Thyroid C-Cell Tumors: GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) have caused thyroid C-cell tumors in rodent studies; human relevance has not been determined. Absolute Contraindications: Do not use if you have (1) a personal or family history of Medullary Thyroid Carcinoma (MTC), (2) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), (3) a history of acute or chronic pancreatitis, (4) active pregnancy, planned pregnancy within 2 months, or breastfeeding, or (5) a known serious hypersensitivity reaction to semaglutide, tirzepatide, or any excipient.

Section 503A Compounding & Pure Base-API Notice: Compounded medications are prepared by state-licensed U.S. Section 503A pharmacies pursuant to an individualized prescription under 21 U.S.C. § 353a and are not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness, or quality. Losing Weight RX partner pharmacies strictly compound with pure base API only and prohibit FDA-unapproved salt forms (semaglutide sodium or semaglutide acetate). Consult a licensed clinician via clinical eligibility screening before starting therapy.

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in GLP-1 BMI Calculator: Do You Qualify for Treatment? is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Asiabar, A. S., Rezaei, M. A., Jafarzadeh, D., Rajaei, S., Atefimanesh, P., Soleimanpour, S., Meher, M. H. K., & Azari, S. (2024). The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review. European journal of clinical pharmacology, 80(12), 1857-1870. https://doi.org/10.1007/s00228-024-03755-w
  2. Harvard Health Publishing, Harvard Medical School. (2024). How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond. https://www.health.harvard.edu/staying-healthy/how-does-ozempic-work-understanding-glp-1s-for-diabetes-weight-loss-and-beyond
  3. Liu, L., Cui, J., Neidecker, M. V., & Nahata, M. C. (2025). Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States. Journal of managed care & specialty pharmacy, 31(5), 441-450. https://doi.org/10.18553/jmcp.2025.31.5.441
  4. National Heart, Lung, and Blood Institute, National Institutes of Health. (2024). Overweight and obesity: Treatment. https://www.nhlbi.nih.gov/health/overweight-and-obesity/treatment
  5. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  6. Wang, S., Fan, D., Yao, Q., & Sun, X. (2025). The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China. Diabetes, obesity & metabolism, 27(9), 5269-5279. https://doi.org/10.1111/dom.16580